Literature DB >> 6652963

The role of the spleen in the protective effect of C-reactive protein in Streptococcus pneumoniae infection.

S Nakayama, H Gewurz, T Holzer, T W Du Clos, C Mold.   

Abstract

C-reactive protein (CRP) is an acute phase serum protein in man which activates complement and has opsonic activity. We have reported that prior injection of CRP into mice can increase their survival following intravenous challenge with Streptococcus pneumoniae type 3 or 4. In this study the conditions required for protection, and the role of hepatic and splenic clearance of bacteria have been examined. Protection against lethal infection was observed with a minimum dose of 25-50 micrograms CRP per mouse. CRP was most effective when administered between 6 h before and 2 h after challenge. CRP treated mice were not protected against infection with Salmonella typhimurium, LT-2, an organism which does not bind CRP. Mice depleted of C3 by treatment with cobra venom factor were protected against S. pneumoniae infection by CRP. Pre-treatment of mice with CRP did not increase the rate of clearance of viable S. pneumoniae from the bloodstream but did increase splenic and decrease hepatic clearance of radiolabelled bacteria in both normal and complement depleted mice. Although these findings suggest a role for the spleen in CRP protection, mice which had been splenectomized were also protected against lethal pneumococcal infection by CRP treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652963      PMCID: PMC1535889     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria.

Authors:  C O Kindmark
Journal:  Clin Exp Immunol       Date:  1971-06       Impact factor: 4.330

2.  Effect of antibody upon clearance of I-125-labelled pneumococci by the spleen and liver.

Authors:  M L Schulkind; E F Ellis; R T Smith
Journal:  Pediatr Res       Date:  1967-05       Impact factor: 3.756

3.  Studies of human C-reactive protein in an in vitro phagocytic system.

Authors:  R C Williams; P G Quie
Journal:  J Immunol       Date:  1968-09       Impact factor: 5.422

Review 4.  Metabolism of immunoglobulins.

Authors:  T A Waldmann; W Strober
Journal:  Prog Allergy       Date:  1969

5.  The effect of previous splenectomy on the course of pneumococcal bacteriaemia in mice.

Authors:  A N Whitaker
Journal:  J Pathol Bacteriol       Date:  1968-04

6.  The syndrome of asplenia, pneumococcal sepsis, and disseminated intravascular coagulation.

Authors:  A L Bisno; J C Freeman
Journal:  Ann Intern Med       Date:  1970-03       Impact factor: 25.391

7.  Mediation of CRP-dependent phagocytosis through mouse macrophage Fc-receptors.

Authors:  R F Mortensen; J A Duszkiewicz
Journal:  J Immunol       Date:  1977-11       Impact factor: 5.422

8.  Radioimmunoassay of human C-reactive protein and levels in normal sera.

Authors:  D R Claus; A P Osmand; H Gewurz
Journal:  J Lab Clin Med       Date:  1976-01

9.  Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis.

Authors:  R F Mortensen; A P Osmand; T F Lint; H Gewurz
Journal:  J Immunol       Date:  1976-09       Impact factor: 5.422

10.  Effect of splenectomy on the susceptibility of mice inoculated with Diplococcus pneumoniae.

Authors:  H R Shinefield; C R Steinberg; D Kaye
Journal:  J Exp Med       Date:  1966-05-01       Impact factor: 14.307

View more
  16 in total

1.  Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide.

Authors:  Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson; Alok Agrawal
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

2.  Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice.

Authors:  A J Szalai; J L VanCott; J R McGhee; J E Volanakis; W H Benjamin
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

Review 4.  C-reactive protein: structural biology, gene expression, and host defense function.

Authors:  A J Szalai; A Agrawal; T J Greenhough; J E Volanakis
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

5.  Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis.

Authors:  A Wellmer; J Gerber; J Ragheb; G Zysk; T Kunst; A Smirnov; W Brück; R Nau
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae.

Authors:  A J Szalai; D E Briles; J E Volanakis
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

7.  C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms.

Authors:  Toh B Gang; Gregory A Hanley; Alok Agrawal
Journal:  Infect Immun       Date:  2015-02-17       Impact factor: 3.441

Review 8.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

9.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

10.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

Authors:  D M Vigushin; M B Pepys; P N Hawkins
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.